Siegel RL, Miller KD, Jemal A.Cancer statistics,2017[J].CA Cancer J Clin, 2017, 67(1):7-30 [2]Chen W, Zheng R, Baade PD, et al.Cancer statistics in China,2015[J].CA Cancer J Clin, 2016, 66(2):115-132 [3]Swisher EM, Taniguchi T, Karlan BY.Molecular scores to predict ovarian cancer outcomes: a worthy goal,but not ready for prime time[J].J Natl Cancer Inst, 2012, 104(9):642-645 [4]Saxena A, Carninci P.Long non-coding RNA modifies chromatin: epigenetic silencing by long non-coding RNAs[J].Bioessays, 2011, 33(11):830-839 [5]Worku T, Bhattarai D, Ayers D, et al.Long non-coding RNAs: the new horizon of gene regulation in ovarian cancer[J].Cell Physiol Biochem, 2017, 44(3):948-966 [6]Pan Y, Li C, Chen J, et al.The emerging roles of long noncoding RNA ROR (lincRNA-ROR) and its possible mechanisms in human cancers[J].Cell Physiol Biochem, 2016, 40(1-2):219- [7]Wang Y, Wang H, Song T, et al.HOTAIR is a potential target for the treatment of cisplatin resistant ovarian cancer[J].Mol Med Rep, 2015, 12(2):2211-2216 [8]Nikpayam E, Tasharrofi B, Sarrafzadeh S, et al.The Role of Long Non-Coding RNAs in Ovarian Cancer[J].Iran Biomed J, 2017, 21(1):3-15 [9]Liu S, Jiang X, Li W, et al.Inhibition of the long non-coding RNA MALAT1 suppresses tumorigenicity and induces apoptosis in the human ovarian cancer SKOV3 cell line[J].Oncol Lett, 2016, 11(6):3686-3692 [10]Zou A, Liu R, Wu X.Long non-coding RNA MALAT1 is up-regulated in ovarian cancer tissue and promotes SK-OV-3 cell proliferation and invasion[J].Neoplasma, 2016, 63(6):865-872 [11]Zhou Y, Xu X, Lv H, et al.The long noncoding RNA MALAT-1 is highly expressed in ovarian cancer and induces cell growth and migration[J].PLoS One, 2016, 11(5):e0155250- [12]Wu DD, Chen X, Sun KX, et al.Role of the lncRNA ABHD11-AS1 in the tumorigenesis and progression of epithelial ovarian cancer through targeted regulation of RhoC[J].Mol Cancer, 2017, 16(1):138- [13]Richards EJ, Permuth-Wey J, Li Y, et al.A functional variant in HOXA11-AS,a novel long non-coding RNA,inhibits the oncogenic phenotype of epithelial ovarian cancer[J].Oncotarget, 2015, 6(33):34745-34757 [14]Teschendorff AE, Lee SH, Jones A, et al.HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer[J]. Genome Med, 2015, 7: 108 [15]Li J, Yu H, Xi M, et al.Long noncoding RNA C17orf91 is a potential prognostic marker and functions as an oncogene in ovarian cancer[J].J Ovarian Res, 2016, 9(1):49- [16]Li J, Huang H, Li Y, et al.Decreased expression of long non-coding RNA GAS5 promotes cell proliferation,migration and invasion,and indicates a poor prognosis in ovarian cancer[J].Oncol Rep, 2016, 36(6):3241-3250 [17]Hu X, Feng Y, Zhang D.A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer[J].Cancer Cell, 2014, 26(3):344-357 [18]Kuang D, Zhang X, Hua S, et al.Long non-coding RNA TUG1 regulates ovarian cancer proliferation and metastasis via affecting epithelial-mesenchymal transition[J].Exp Mol Pathol, 2016, 101(2):267-273 [19]Chen ZJ, Zhang Z, Xie BB, et al.Clinical significance of up-regulated lncRNA NEAT1 in prognosis of ovarian cancer[J].Eur Rev Med Pharmacol Sci, 2016, 20(16):3373-3377 [20]Huang S, Qing C, Huang Z, et al.The long non-coding RNA CCAT2 is up-regulated in ovarian cancer and associated with poor prognosis[J].Diagn Pathol, 2016, 11(1):49-
